Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Isaacs

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
European Journal of Pharmacology|May 29, 2018
Identification of compounds acting as negative allosteric modulators of the LPA<sub>1</sub> receptorJonathan Ellery, Louise Dickson, Toni Cheung, et al.
BMC Cancer|October 3, 2014
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II studyChristopher G C A Jackson, Katrina Sharples, Paul I Thompson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 20, 2025
Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN)Navin Wewala, Yujin Kim, Katrina Sharples, et al.
Cancers|July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCeleste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGuy A van Hazel, Volker Heinemann, Navesh K Sharma, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
European Journal of Pharmacology|May 29, 2018
Identification of compounds acting as negative allosteric modulators of the LPA<sub>1</sub> receptorJonathan Ellery, Louise Dickson, Toni Cheung, et al.
BMC Cancer|October 3, 2014
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II studyChristopher G C A Jackson, Katrina Sharples, Paul I Thompson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 20, 2025
Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN)Navin Wewala, Yujin Kim, Katrina Sharples, et al.
Cancers|July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCeleste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGuy A van Hazel, Volker Heinemann, Navesh K Sharma, et al.
Pageof 2